文献速递MDS 与骨髓增殖性肿瘤

组蛋白甲基转移酶DOT1L与LSD1协同调控急变期MPN细胞分裂

The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN.
PubMed 文献 · Leukemia · 2025-08-08

该研究通过染色质聚焦的CRISPR-Cas9筛选发现,在药物抑制LSD1的条件下,组蛋白甲基转移酶DOT1L成为合成致死靶点;DOT1L敲除损害细胞适应性、减少增殖并延长异种移植模型生存,且DOT1L遗传失活使TP53突变急变期MPN对LSD1抑制剂敏感性提高至100倍,诱导细胞周期阻滞和凋亡。

要点

  • 染色质聚焦CRISPR-Cas9筛选鉴定DOT1L为LSD1抑制下的合成致死靶点。
  • DOT1L敲除损害细胞适应性、减少增殖并延长异种移植模型生存。
  • DOT1L遗传失活使TP53突变急变期MPN对LSD1抑制剂敏感性提高至100倍。

核心结论

  • 通过蛋白降解或RNA干扰靶向DOT1L而非传统酶活性抑制,可能增强LSD1抑制剂在急变期MPN中的疗效。

研究设计与样本

  • 研究采用染色质聚焦的CRISPR-Cas9筛选,并在TP53突变急变期MPN模型及异种移植模型中验证。

主要发现

  • DOT1L敲除损害细胞适应性、减少增殖并延长异种移植模型生存。
  • DOT1L遗传失活使LSD1抑制剂敏感性提高至100倍,导致TP53突变急变期MPN细胞周期阻滞和凋亡诱导。
  • DOT1L与LSD1共占增强子并参与抑制转录程序,该功能不依赖其酶活性。
  • DOT1L缺失与LSD1抑制剂协同激活肿瘤抑制程序,而药物抑制DOT1L催化活性未能产生 comparable 效果。

临床怎么用

  • 作者认为,通过蛋白降解或RNA干扰靶向DOT1L而非传统酶活性抑制,可能增强LSD1抑制剂在急变期MPN中的疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Persistence of JAK2-mutated clones that may undergo clonal evolution and malignant transformation remains a challenge in myeloproliferative neoplasms (MPN), Novel therapeutic approaches to attenuate clonal evolution and progression to blast-phase are therefore urgently needed. LSD1 (KDM1A) inhibitors reduce symptoms and clonal burden in MPN, but whether these compounds may be effective in advanced disease stages remained so far elusive. Using a chromatin-focused CRISPR-Cas9 screen, we identified the histone methyltransferase DOT1L as a synthetic lethal target under pharmacologic LSD1 inhibition. DOT1L knockout impaired cellular fitness, reduced proliferation, and prolonged survival in xenografts. Furthermore, genetic inactivation of DOT1L increased LSD1 inhibitor sensitivity up to 100-fold resulting in cell cycle arrest and apoptosis induction in TP53 mutant blast-phase MPN. Mechanistically, we have identified a novel, non-canonical function of DOT1L which co-occupied LSD1-bound enhancers and contributed to the repression of transcriptional programs independent of its enzymatic activity. DOT1L loss cooperated with LSD1 inhibitors to activate tumor suppressive programs, while pharmacologic inhibition of DOT1Ls catalytic activity failed to elicit comparable effects. These findings indicate that leveraging DOT1L targeting via protein degradation or RNA interference, rather than conventional enzymatic inhibition, could enhance the therapeutic efficacy of LSD1 inhibitors in blast-phase MPN.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kapahnke K, Plenge T, Klaus T, et al. The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN. Leukemia. 2025. PMID: 40781484. doi:10.1038/s41375-025-02719-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。